drugset / Trial / NCT05297903
XmAb20717 in Advanced Biliary Tract Cancers
NaSingle-groupOpen-labelTreatment
Summary
This is a single-arm, phase II clinical trial to evaluate the efficacy of XmAb20717 in patients with advanced biliary tract cancers who have progressed on, or were intolerant of, a gemcitabine-based chemotherapy regimen.
Timeline
- Start
- 2022-04-11
- Primary completion
- 2026-07-13
- Completion
- 2026-07-13
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Vudalimab | Monoclonal antibody | 10 mg/kg | Intravenous |